REPORT ID 3392

EMEA (Europe, Middle East and Africa) Female Hypoactive Sexual Desire Disorder Therapeutics Market Report 2017

Publish Date
13-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the EMEA Female Hypoactive Sexual Desire Disorder Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Female Hypoactive Sexual Desire Disorder Therapeutics for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Female Hypoactive Sexual Desire Disorder Therapeutics market competition by top manufacturers/players, with Female Hypoactive Sexual Desire Disorder Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Emotional Brain BV
    GlaxoSmithKline Plc
    Palatin Technologies Inc
    Pivot Pharmaceuticals Inc
    Strategic Science & Technologies LLC
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    BP-101
    Bremelanotide
    Gepirone Hydrochloride ER
    PVT-011
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Out-Patient
    In-Patient

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Female Hypoactive Sexual Desire Disorder Therapeutics Market Report 2017
1 Female Hypoactive Sexual Desire Disorder Therapeutics Overview
    1.1 Product Overview and Scope of Female Hypoactive Sexual Desire Disorder Therapeutics
    1.2 Classification of Female Hypoactive Sexual Desire Disorder Therapeutics
        1.2.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 BP-101
        1.2.4 Bremelanotide
        1.2.5 Gepirone Hydrochloride ER
        1.2.6 PVT-011
        1.2.7 Others
    1.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market by Application/End Users
        1.3.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Out-Patient
        1.3.3 In-Patient
    1.4 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market by Region
        1.4.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Female Hypoactive Sexual Desire Disorder Therapeutics (2012-2022)
        1.5.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Growth Rate (2012-2022)

2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market Competition by Players/Manufacturers
        2.1.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sale Price by Players (2012-2017)
    2.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sale Price by Type (2012-2017)
    2.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics (Volume) by Application
    2.4 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics (Volume and Value) by Region
        2.4.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales Price by Region (2012-2017)

3 Europe Female Hypoactive Sexual Desire Disorder Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Value (2012-2017)
        3.1.1 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Growth Rate (2012-2017)
    3.2 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Type
    3.3 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Application
    3.4 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume by Countries (2012-2017)
        3.4.2 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries (2012-2017)
        3.4.3 Germany Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        3.4.4 France Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        3.4.5 UK Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        3.4.6 Russia Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        3.4.7 Italy Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)

4 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Value (2012-2017)
        4.1.1 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Growth Rate (2012-2017)
    4.2 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Type
    4.3 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Application
    4.4 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        4.4.4 Israel Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        4.4.5 UAE Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        4.4.6 Iran Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)

5 Africa Female Hypoactive Sexual Desire Disorder Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Value (2012-2017)
        5.1.1 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Growth Rate (2012-2017)
    5.2 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Type
    5.3 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Market Share by Application
    5.4 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales Volume by Countries (2012-2017)
        5.4.2 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries (2012-2017)
        5.4.3 South Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate (2012-2017)

6 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Manufacturers/Players Profiles and Sales Data
    6.1 Emotional Brain BV
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Female Hypoactive Sexual Desire Disorder Therapeutics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Emotional Brain BV Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 GlaxoSmithKline Plc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Female Hypoactive Sexual Desire Disorder Therapeutics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 GlaxoSmithKline Plc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Palatin Technologies Inc
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Female Hypoactive Sexual Desire Disorder Therapeutics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Palatin Technologies Inc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Pivot Pharmaceuticals Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Female Hypoactive Sexual Desire Disorder Therapeutics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Pivot Pharmaceuticals Inc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Strategic Science & Technologies LLC
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Female Hypoactive Sexual Desire Disorder Therapeutics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Strategic Science & Technologies LLC Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    ...

7 Female Hypoactive Sexual Desire Disorder Therapeutics Manufacturing Cost Analysis
    7.1 Female Hypoactive Sexual Desire Disorder Therapeutics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Female Hypoactive Sexual Desire Disorder Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Female Hypoactive Sexual Desire Disorder Therapeutics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Female Hypoactive Sexual Desire Disorder Therapeutics Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Market Forecast (2017-2022)
    11.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Price and Trend Forecast (2017-2022)
    11.2 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales Forecast by Type (2017-2022)
    11.7 EMEA Female Hypoactive Sexual Desire Disorder Therapeutics Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer